Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Tab Desidustat: Oral HIF PHI analogue approved for CKD Anemia patients.
Started at dose corresponding to EPO Dosage of 10,000U (125 mg) for 8 weeks.
Control Intervention1: Eryhtropoieti
Sponsors
Department Of Nephrology P.G.I.M.E.R. Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: Chronic Kidney Disease Patients- Non-Dialysis Dependent CKD Dialysis dependent patients on adequate dialysis i.e.2/3 times a week Ferritin >100 ng/dl T Sat >20%
Exclusion criteria
Exclusion criteria: Haematological Malignancy Hemoglobinopathies Active Bleeding Sepsis or Septic Shock HIV Systemic Immunosupression Therapy Pregnancy / Lactation Severe Hyperparathyroidism ( Intact PTH >9 times normal )
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Hemoglobin levels from baseline to 8 weeksTimepoint: from baseline to 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Change in iron profile parameters (Serum Iron, Transferrin saturation, Total iron binding capacity, Ferritin) 2. Inflammatory markers (IL1, IL6, Hepcidin, CRP)Timepoint: Baseline and at the end of 2 months | — |
Countries
India
Contacts
Public ContactDr Nikhil Bajiya
Post Graduate Institute of Medical Education and Research, Chandigarh
Outcome results
None listed